Tomasz Beer, MD, FACP, professor of medicine, deputy director of the Knight Cancer Institute, Oregon Health and Science University, characterizes the immune-related adverse events associated with ipilimumab in a phase III metastatic castration-resistant prostate cancer trial.
Tomasz Beer, MD, FACP, professor of medicine, deputy director of the Knight Cancer Institute, Oregon Health and Science University, characterizes the immune-related adverse events associated with ipilimumab in a phase III metastatic castration-resistant prostate cancer trial.
Beer says the study was an analysis of the results of the first, large, randomized study of ipilimumab in advanced prostate cancer. Ipilimumab is an immune modulator that works by breaking tolerance and stimulating the immune system so that it can recognize and attack the prostate cancer.
Since ipilimumab is not specific to a cancer antigen, Beer says, it causes side effects that are related to an overactive immune system. Data from the analysis, which was presented at the 2014 Genitourinary Cancers Symposium, showed that the side effect profile of ipilimumab in prostate cancer is similar to what was previously described in melanoma, where the drug is approved.
Beer says standard approaches to the management of these side effects are almost always effective.
Navigating the Intersection of Radiation Therapy and Immunotherapy in Endometrial Cancer
As Orthopedic Oncology Evolves, Caring for the Clinician Must Be a Priority
Belumosudil Produces Long-Term Responses Without New Safety Concerns in cGVHD
Prophylactic Itacitinib May Safely Mitigate CRS Following Axi-Cel Administration in Lymphoma
2 Commerce Drive
Cranbury, NJ 08512